Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
HIV BINDING AGENTS
Document Type and Number:
WIPO Patent Application WO/2021/009697
Kind Code:
A3
Abstract:
This disclosure relates to LN02M binding agents with specificity for HIV and to methods for using the same to treat, prevent and / or ameliorate HIV infection and/or AIDS. In some embodiments, this disclosure provides a binding agent(s) comprising a variable region shown in Figs. 6A through 6E; amino acid sequence of any mutant of Figs. 7A through 7D and/or Figs. 8A through 8F, and any effective (e.g., HIV neutralization) combination thereof; any one or more of SEQ ID NOS. 3-92, 95-233, 248-482, or 491-699; and/or combinations thereof.

Inventors:
PANTALEO GIUSEPPE (CH)
FENWICK CRAIG (CH)
Application Number:
PCT/IB2020/056668
Publication Date:
April 15, 2021
Filing Date:
July 15, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
LAUSANNE UNIV HOSPITAL (CH)
International Classes:
A61P31/18; C07K16/10
Domestic Patent References:
WO2017093985A12017-06-08
Other References:
GIUSEPPE PANTALEO ET AL: "Pantaleo: Optimization of the LN02 Anti-HIV Broadly Neutralizing Antibody Principal Investigator Grantee Institution Optimization of the LN02 Anti-HIV Broadly Neutralizing Antibody Collaborating Institutions", 1 April 2018 (2018-04-01), XP055744474, Retrieved from the Internet [retrieved on 20201027]
ANONYMOUS ET AL: "Purpose: to optimize a novel broadly neutralizing antibody against HIV, LN02, and evaluate its potential for future clinical development", 1 May 2018 (2018-05-01), XP055744469, Retrieved from the Internet [retrieved on 20201027]
GIUSEPPE PANTALEO ET AL: "Pantaleo: Generation/Isolation of Novel bnAbs from Lymph Node B cells Principal Investigator Grantee Institution Collaborating Institutions", 1 November 2014 (2014-11-01), XP055744468, Retrieved from the Internet [retrieved on 20201027]
Download PDF: